148 related articles for article (PubMed ID: 34586478)
1. Population pharmacokinetic analysis of crizotinib in children with progressive/recurrent high-grade and diffuse intrinsic pontine gliomas.
Gibson EG; Campagne O; Selvo NS; Gajjar A; Stewart CF
Cancer Chemother Pharmacol; 2021 Dec; 88(6):1009-1020. PubMed ID: 34586478
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma.
Broniscer A; Jia S; Mandrell B; Hamideh D; Huang J; Onar-Thomas A; Gajjar A; Raimondi SC; Tatevossian RG; Stewart CF
Pediatr Blood Cancer; 2018 Jul; 65(7):e27035. PubMed ID: 29512900
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial of lenalidomide and radiotherapy in children with diffuse intrinsic pontine gliomas or high-grade gliomas.
Hipp SJ; Goldman S; Kaushal A; Krauze A; Citrin D; Glod J; Walker K; Shih JH; Sethumadhavan H; O'Neill K; Garvin JH; Glade-Bender J; Karajannis MA; Atlas MP; Odabas A; Rodgers LT; Peer CJ; Savage J; Camphausen KA; Packer RJ; Figg WD; Warren KE
J Neurooncol; 2020 Sep; 149(3):437-445. PubMed ID: 33040274
[TBL] [Abstract][Full Text] [Related]
4. Characterizing the pharmacokinetics of panobinostat in a non-human primate model for the treatment of diffuse intrinsic pontine glioma.
Rodgers LT; Lester McCully CM; Odabas A; Cruz R; Peer CJ; Figg WD; Warren KE
Cancer Chemother Pharmacol; 2020 Apr; 85(4):827-830. PubMed ID: 31894347
[TBL] [Abstract][Full Text] [Related]
5. A phase I/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG).
DeWire M; Fuller C; Hummel TR; Chow LML; Salloum R; de Blank P; Pater L; Lawson S; Zhu X; Dexheimer P; Carle AC; Kumar SS; Drissi R; Stevenson CB; Lane A; Breneman J; Witte D; Jones BV; Leach JL; Fouladi M
J Neurooncol; 2020 Sep; 149(3):511-522. PubMed ID: 33034839
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma.
Broniscer A; Baker SD; Wetmore C; Pai Panandiker AS; Huang J; Davidoff AM; Onar-Thomas A; Panetta JC; Chin TK; Merchant TE; Baker JN; Kaste SC; Gajjar A; Stewart CF
Clin Cancer Res; 2013 Jun; 19(11):3050-8. PubMed ID: 23536435
[TBL] [Abstract][Full Text] [Related]
7. A phase 2 study of valproic acid and radiation, followed by maintenance valproic acid and bevacizumab in children with newly diagnosed diffuse intrinsic pontine glioma or high-grade glioma.
Su JM; Murray JC; McNall-Knapp RY; Bowers DC; Shah S; Adesina AM; Paulino AC; Jo E; Mo Q; Baxter PA; Blaney SM
Pediatr Blood Cancer; 2020 Jun; 67(6):e28283. PubMed ID: 32285998
[TBL] [Abstract][Full Text] [Related]
8. Real-Time, in Vivo Correlation of Molecular Structure with Drug Distribution in the Brain Striatum Following Convection Enhanced Delivery.
Tosi U; Kommidi H; Bellat V; Marnell CS; Guo H; Adeuyan O; Schweitzer ME; Chen N; Su T; Zhang G; Maachani UB; Pisapia DJ; Law B; Souweidane MM; Ting R
ACS Chem Neurosci; 2019 May; 10(5):2287-2298. PubMed ID: 30838861
[TBL] [Abstract][Full Text] [Related]
9. Intraarterial delivery of bevacizumab and cetuximab utilizing blood-brain barrier disruption in children with high-grade glioma and diffuse intrinsic pontine glioma: results of a phase I trial.
McCrea HJ; Ivanidze J; O'Connor A; Hersh EH; Boockvar JA; Gobin YP; Knopman J; Greenfield JP
J Neurosurg Pediatr; 2021 Aug; 28(4):371-379. PubMed ID: 34359048
[TBL] [Abstract][Full Text] [Related]
10. Design considerations of an IL13Rα2 antibody-drug conjugate for diffuse intrinsic pontine glioma.
Lian X; Kats D; Rasmussen S; Martin LR; Karki A; Keller C; Berlow NE
Acta Neuropathol Commun; 2021 May; 9(1):88. PubMed ID: 34001278
[TBL] [Abstract][Full Text] [Related]
11. Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children's Oncology Group phase 1 consortium study (ADVL1212).
Greengard E; Mosse YP; Liu X; Minard CG; Reid JM; Voss S; Wilner K; Fox E; Balis F; Blaney SM; Adamson PC; Weigel BJ
Cancer Chemother Pharmacol; 2020 Dec; 86(6):829-840. PubMed ID: 33095287
[TBL] [Abstract][Full Text] [Related]
12. ABC Transporter Inhibition Plus Dexamethasone Enhances the Efficacy of Convection Enhanced Delivery in H3.3K27M Mutant Diffuse Intrinsic Pontine Glioma.
Tsvankin V; Hashizume R; Katagi H; Herndon JE; Lascola C; Venkatraman TN; Picard D; Burrus B; Becher OJ; Thompson EM
Neurosurgery; 2020 May; 86(5):742-751. PubMed ID: 31225627
[TBL] [Abstract][Full Text] [Related]
13. Differential Expression of Wilms' Tumor Protein in Diffuse Intrinsic Pontine Glioma.
Lee S; Kambhampati M; Yadavilli S; Gordish-Dressman H; Santi M; Cruz CR; Packer RJ; Almira-Suarez MI; Hwang EI; Nazarian J
J Neuropathol Exp Neurol; 2019 May; 78(5):380-388. PubMed ID: 30990879
[TBL] [Abstract][Full Text] [Related]
14. Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children's Hospital experience.
Crotty EE; Leary SES; Geyer JR; Olson JM; Millard NE; Sato AA; Ermoian RP; Cole BL; Lockwood CM; Paulson VA; Browd SR; Ellenbogen RG; Hauptman JS; Lee A; Ojemann JG; Vitanza NA
J Neurooncol; 2020 Jul; 148(3):607-617. PubMed ID: 32556862
[TBL] [Abstract][Full Text] [Related]
15. Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma.
Bartels U; Wolff J; Gore L; Dunkel I; Gilheeney S; Allen J; Goldman S; Yalon M; Packer RJ; Korones DN; Smith A; Cohen K; Kuttesch J; Strother D; Baruchel S; Gammon J; Kowalski M; Bouffet E
Neuro Oncol; 2014 Nov; 16(11):1554-9. PubMed ID: 24847085
[TBL] [Abstract][Full Text] [Related]
16. ALK2 inhibitors display beneficial effects in preclinical models of
Carvalho D; Taylor KR; Olaciregui NG; Molinari V; Clarke M; Mackay A; Ruddle R; Henley A; Valenti M; Hayes A; Brandon AH; Eccles SA; Raynaud F; Boudhar A; Monje M; Popov S; Moore AS; Mora J; Cruz O; Vinci M; Brennan PE; Bullock AN; Carcaboso AM; Jones C
Commun Biol; 2019; 2():156. PubMed ID: 31098401
[TBL] [Abstract][Full Text] [Related]
17. Development of a clinical scale for assessment of patients with diffuse intrinsic pontine glioma (DIPG) receiving experimental therapy: the PONScore.
Hollingworth MA; Zacharoulis S
J Neurooncol; 2020 Sep; 149(2):263-272. PubMed ID: 32902768
[TBL] [Abstract][Full Text] [Related]
18. Identification of Novel RAS Signaling Therapeutic Vulnerabilities in Diffuse Intrinsic Pontine Gliomas.
Koncar RF; Dey BR; Stanton AJ; Agrawal N; Wassell ML; McCarl LH; Locke AL; Sanders L; Morozova-Vaske O; Myers MI; Hamilton RL; Carcaboso AM; Kohanbash G; Hu B; Amankulor NM; Felker J; Kambhampati M; Nazarian J; Becher OJ; James CD; Hashizume R; Broniscer A; Pollack IF; Agnihotri S
Cancer Res; 2019 Aug; 79(16):4026-4041. PubMed ID: 31201162
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E
J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423
[TBL] [Abstract][Full Text] [Related]
20. A pilot study of bevacizumab-based therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas.
Hummel TR; Salloum R; Drissi R; Kumar S; Sobo M; Goldman S; Pai A; Leach J; Lane A; Pruitt D; Sutton M; Chow LM; Grimme L; Doughman R; Backus L; Miles L; Stevenson C; Fouladi M; DeWire M
J Neurooncol; 2016 Mar; 127(1):53-61. PubMed ID: 26626490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
